Medlab breaks new ground in the UK

Medlab breaks new ground in the UK

Listed medicinal cannabis player Medlab Clinical (ASX: MDC) has signed an exclusive distribution agreement with Cultech to break into the UK market.

Cultech, a premium manufacturer in the nutritional supplement industry, will distribute two of Medlab's flaghship products in the country.

One of those two products is Medlab's NanoCBD product: a cannabinoid-based product that utilises the properties of Magnesium.

Cultech will also distribute Medlab's ORSBiotic product which fits under the Australian company's nutraceutical umbrella.

"Our IP has commercial reality, and whilst we have medical and scientific validation, the real-world validation is the commercial opportunities," says Medlab CEO Dr Sean Hall.

"Medlab remains true to its IPO promise of finding good partners to provide longevity in commercial relationships. Regarding Cultech, I have worked with them for well over a decade and they are uniquely placed to expand trade into territories beyond the United Kingdom."

The deal with Cultech follows Medlab's expansion of its nutraceutical business into the US.

Under the agreement Medlab will benefit from minimal operating expenditure exposure, and provides for 20 per cent royalties ex-factory under the transfer agreement.

At the end of FY19 Medlab remains unprofitable, despite seeing its revenue rise by 46 per cent to $8.09 million.

The company recorded a loss of $8.09 million, which mirrors the results of fellow listed cannabis companies like CannPal Animal Therapeutics and AusCann Group who both reported FY19 losses.

Medlab was named the number seven top cannabis company in Australia by Business News Australia.

Shares in Medlab Clinical are up 11.67 per cent to $0.34 per share at 11.07am AEDT.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

“Not our desired outcome”: Telix withdraws from $300m Nasdaq IPO

“Not our desired outcome”: Telix withdraws from $300m Nasdaq IPO

Telix Pharmaceuticals (ASX: TLX), one of the nation’s largest...

CommBank joins new ‘intelligence loop’ to combat SMS phishing scams

CommBank joins new ‘intelligence loop’ to combat SMS phishing scams

In an effort to reduce the number of SMS phishing scam victims...

Stralis Aircraft secures funding to make commercial hydrogen planes a reality

Stralis Aircraft secures funding to make commercial hydrogen planes a reality

Brisbane-based Stralis Aircraft has become one step closer to its a...

‘Gone the long yards’: Luxury boatbuilder Maritimo a stayer in local manufacturing

‘Gone the long yards’: Luxury boatbuilder Maritimo a stayer in local manufacturing

In an era when Australia’s mass-production car industry is a ...